InterMune Provides Program Update and 2010 Milestones for RG7227 (ITMN-191)

Tuesday, January 12, 2010 General News
Email Print This Page Comment bookmark
Font : A-A+

Milestones and Key Events

Expected Date

Un-blinded rapid virologic response (RVR) and early virologic response (EVR) data from the on-going Phase 2b study of RG7227 plus SOC (un-boosted 12-week regimens)

Late Q1 or early Q2 2010 (updated guidance with additional data reported)

Initiation of INFORM-2 program (ritonavir-boosted RG7227 plus RG7128)

Q1 2010: Timing subject to change due to integration of new ritonavir boosting strategy

Initiation of longer duration DAA study to evaluate SVR (ritonavir boosted)

Q2 2010: Timing subject to change due to integration of new ritonavir boosting strategy

Initiation of Phase 2b study of ritonavir-boosted RG7227 plus SOC

Q3 2010 (new study)



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook